Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Mol Pharm. 2018 Aug 6;15(8):3557-3572. doi: 10.1021/acs.molpharmaceut.8b00547. Epub 2018 Jul 10.

Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process.

Author information

1
Department of Molecular and Clinical Pharmacology , University of Liverpool , Liverpool L69 3GL , U.K.
2
Department of Molecular and Clinical Cancer Medicine , University of Liverpool , Liverpool L69 3BX , U.K.
3
Liverpool Hepatobiliary Unit , University Hospital Aintree , Liverpool L9 7AL , U.K.
4
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology , 70376 Stuttgart , Germany.
5
University Tübingen , Tübingen , Germany.
6
Department of Clinical Pharmacology , University Hospital Tübingen , 72076 Tubingen , Germany.
7
Department of Pharmacy and Biochemistry , University Tübingen , 72076 Tübingen , Germany.

Abstract

The weak base antipsychotic clozapine is the most effective medication for treating refractory schizophrenia. The brain-to-plasma concentration of unbound clozapine is greater than unity, indicating transporter-mediated uptake, which has been insufficiently studied. This is important, because it could have a significant impact on clozapine's efficacy, drug-drug interaction, and safety profile. A major limitation of clozapine's use is the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), which is a rare but severe hematological adverse drug reaction. We first studied the uptake of clozapine into human brain endothelial cells (hCMEC/D3). Clozapine uptake into cells was consistent with a carrier-mediated process, which was time-dependent and saturable ( Vmax = 3299 pmol/million cells/min, Km = 35.9 μM). The chemical inhibitors lamotrigine, quetiapine, olanzapine, prazosin, verapamil, indatraline, and chlorpromazine reduced the uptake of clozapine by up to 95%. This could in part explain the in vivo interactions observed in rodents or humans for these compounds. An extensive set of studies utilizing transporter-overexpressing cell lines and siRNA-mediated transporter knockdown in hCMEC/D3 cells showed that clozapine was not a substrate of OCT1 (SLC22A1), OCT3 (SLC22A3), OCTN1 (SLC22A4), OCTN2 (SLC22A5), ENT1 (SLC29A1), ENT2 (SLC29A2), and ENT4/PMAT (SLC29A4). In a recent genome-wide analysis, the hepatic uptake transporters SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) were identified as additional candidate transporters. We therefore also investigated clozapine transport into OATP1B-transfected cells and found that clozapine was neither a substrate nor an inhibitor of OATP1B1 and OATP1B3. In summary, we have identified a carrier-mediated process for clozapine uptake into brain, which may be partly responsible for clozapine's high unbound accumulation in the brain and its drug-drug interaction profile. Cellular clozapine uptake is independent from currently known drug transporters, and thus, molecular identification of the clozapine transporter will help to understand clozapine's efficacy and safety profile.

KEYWORDS:

SLC transporters; agranulocytosis; blood−brain barrier; clozapine; drug transport; organic anion transporter; organic cation transporter; schizophrenia

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center